Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, a Texas-based biopharmaceutical company, pioneers in developing treatments for human diseases since 1995.
Founded
1995Lexicon Pharmaceuticals, a Texas-based biopharmaceutical company, pioneers in developing treatments for human diseases since 1995.
Founded in 1995 in The Woodlands, Texas, Lexicon Pharmaceuticals is a biopharmaceutical company dedicated to developing transformative treatments for human diseases. Co-founded by Professor Allan Bradley, FRS, and Dr. Arthur T Sands, the company leverages its patented mouse gene knockout technology and extensive in vivo screening capabilities. Lexicon focuses on therapeutic areas such as heart failure and neuropathic pain, aiming to bring innovative therapies to market through its unique approach to gene science.
Notable figures associated with Lexicon include its co-founders, Professor Allan Bradley and Dr. Arthur T Sands. The company has achieved significant milestones, including the identification of over 100 potential drug targets through its Genome5000 program. Lexicon's pioneering work has had a substantial impact on the biopharmaceutical industry, advancing precision medicine and improving patient outcomes with novel therapies.
Companies similar to Lexicon Pharmaceuticals include Ligand Pharmaceuticals, Biolex Therapeutics, Kiniksa Pharmaceuticals and Filana Therapeutics.
Lexicon Pharmaceuticals was founded in 1995.
Lexicon Pharmaceuticals' headquarters is located in The Woodlands, TX, US.
Lexicon Pharmaceuticals' most recent funding round was for $72.2M (USD) in June 2023.
As of Jun 20, 2023, Lexicon Pharmaceuticals has disclosed funding of $563.6M (USD). Undisclosed round amounts are excluded.
Lexicon Pharmaceuticals has 135 employees as of Feb 6, 2024.
Filana Therapeutics
